Conflicting effects of atazanavir therapy on atherosclerotic risk factors in stable HIV patients: A randomized trial of regimen switch to atazanavir

Bilirubin acts as a potent endogenous antioxidant, with higher concentrations associated with lower rates of CVD; the antiretroviral drug atazanavir (ATV) increases bilirubin levels but may also increase von Willebrand factor levels. We tested the hypothesis that increasing endogenous bilirubin usin...

Descripción completa

Detalles Bibliográficos
Autores principales: Beckman, Joshua A., Wood, Brian R., Ard, Kevin L., Price, Christin N., Solomon, Daniel A., Zuflacht, Jonah P., Milian, Jessica, Prenner, Joshua C., Sax, Paul E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5638209/
https://www.ncbi.nlm.nih.gov/pubmed/29023508
http://dx.doi.org/10.1371/journal.pone.0181993

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5638209/
https://www.ncbi.nlm.nih.gov/pubmed/29023508
http://dx.doi.org/10.1371/journal.pone.0181993

Ejemplares similares